Search
Recursion Pharmaceuticals Inc
RXRXAdd to Watchlist
3.050USD
-0.100-3.17%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
1.67BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-3.17%
5 Days
-11.08%
1 Month
-10.82%
6 Months
-29.56%
Year to Date
-25.43%
1 Year
-32.37%
TradingKey Stock Score of Recursion Pharmaceuticals Inc
Currency: USD Updated: 2026-05-13Key Insights
Recursion Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 138 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Recursion Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Recursion Pharmaceuticals Inc Highlights
StrengthsRisks
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 67.54% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 74.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 74.68M.
Overvalued
The company’s latest PE is -2.63, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 388.34M shares, increasing 10.70% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 10.11K shares of this stock.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
6.000
Target Price
+84.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Recursion Pharmaceuticals Inc Info
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Ticker SymbolRXRX
CompanyRecursion Pharmaceuticals Inc
CEOKhan (Najat)
Websitehttps://www.recursion.com/
Related Instruments
+2.61%
+2.75%
+0.31%
+1.07%
+1.72%
+0.96%
+0.05%
-1.40%
+0.17%
+0.35%
-0.11%
+1.06%
+0.18%
-1.03%
+0.34%
-0.49%
0.00%
+1.34%
-1.24%
+2.08%Popular Instruments
97.143
-0.969 (-0.99%)
298.870
+4.070 (+1.38%)
225.830
+5.050 (+2.29%)
4696.170
+8.640 (+0.18%)
494.090
+5.350 (+1.09%)
1447.230
-4.790 (-0.33%)
803.630
+37.050 (+4.83%)
402.620
+15.270 (+3.94%)
79340.890
-328.060 (-0.41%)
445.270
+11.820 (+2.73%)
